TFA Therapeutics RAJAF Growth Metrics (2021-2025)

OTC RAJAF
$9.18 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

TFA Therapeutics Quarterly Growth Metrics

Periods 5 quarters
Latest Dec 2025

TFA Therapeutics reported asset growth of 0.73% for the quarter ended Dec 2025. These growth metrics cover 5 quarters of results from Dec 2021 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

1Y3Y5Y7Y10YAll
Download Data
Growth Metrics Dec2021 Dec2022 Dec2023 Dec2024 Dec2025
Growth Ratios
Assets Growth (1y) 15.48%-35.49%59.24%37.95%0.73%
Assets Growth (3y) 5.86%12.32%30.31%
Assets Growth (5y) 10.51%
Assets (QoQ) 86.45%
Capital Expenditures Growth (3y)Capex Growth (3y) 3.20%
Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) 33,739.12%-93.34%248.58%61.37%-91.42%
Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) 328.33%-27.90%-21.56%
Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) 61.19%
Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) 36.62%
Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) 84,032.97%
Cash from Investing Activities Growth (3y)Cash from Investing Growth (3y) 41.19%
Cash from Operations Growth (1y)Cash from Ops. Growth (1y) -568.90%
Cash from Operations Growth (3y)Cash from Ops. Growth (3y) -111.36%
EBITDA Margin Growth (1y) 42,665.00
EBITDA Margin Growth (3y) 3,161.00
EBIT Growth (1y) 426.41%
EBIT Growth (3y) 139.83%
EBIT Margin Growth (1y) 42,665.00
EBIT Margin Growth (3y) 3,170.00
EBT Growth (1y) 326.15%
EBT Growth (3y) 109.79%
EBT Margin Growth (1y) 41,481.00
EBT Margin Growth (3y) 3,501.00
EPS (Basic) Growth (1y) -2,657.69%11.90%115.84%
EPS (Basic) Growth (3y) 80.16%
EPS (Diluted) Growth (1y) -2,657.69%11.90%115.84%
EPS (Diluted) Growth (3y) 80.16%
FCF Margin Growth (1y) 116,204.00
FCF Margin Growth (3y) 14,408.00
Free Cash Flow Growth (1y)FCF Growth (1y) -1,232.02%
Free Cash Flow Growth (3y)FCF Growth (3y) -25.49%
Gross Margin Growth (1y) -235118.00116,303.00120,855.00
Gross Margin Growth (3y) 2,040.00
Gross Profit Growth (1y) -287.32%39.71%367.97%
Gross Profit Growth (3y) 44.64%
Net Cash Flow Growth (1y)NCF Growth (1y) 105.43%
Net Cash Flow Growth (3y)NCF Growth (3y) 212.46%
Net Income Growth (1y) -2,657.69%313.48%-92.20%
Net Income Growth (3y) 87.51%
Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) -2,657.69%8.01%116.85%
Net Income towards Common Stockholders Growth (3y)Net Income Growth (3y) 84.45%
Net Margin Growth (1y) -480131.00121,227.00361,730.00
Net Margin Growth (3y) 2,826.00
Operating Income Growth (1y)Op. Inc Growth (1y) 426.41%
Operating Income Growth (3y)Op. Inc Growth (3y) 139.83%
Operating Margin Growth (1y) 42,665.00
Operating Margin Growth (3y) 3,170.00
Profit After Tax Growth (1y)PAT Growth (1y) 150.32%
Profit After Tax Growth (3y)PAT Growth (3y) 272.80%
Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) 0.10%-95.59%3,627.67%38.90%-7.08%
Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) 18.02%31.64%263.71%
Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) 16.24%
Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) 82.16%
Return on Sales [ROS] Growth (1y)ROS Growth (1y) 42,665.00
Return on Sales [ROS] Growth (3y)ROS Growth (3y) 3,170.00
Revenue Growth (1y) -94.27%22.98%3,221.42%
Revenue Growth (3y) 32.80%
Total Debt Growth (1y) 11.03%-76.13%310.15%42.99%3.08%
Total Debt Growth (3y) 2.83%11.87%82.17%
Total Debt Growth (5y) 9.89%
Total Debt (QoQ) 633.50%